Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

Inclusion Criteria:

• Age≥15 years old
• Newly diagnosed B-cell acute lymphoblastic leukemia according to the 2016 WHO classification
• The immunophenotype of leukemia cells were CD19 and CD22 positive
• Ph- or Ph- like negative
• Anticipated survival time more than 12 weeks;
• Those who voluntarily participated in this trial and provided informed consent.

Exclusion Criteria:

• History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
• Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
• Pregnant (or lactating) women;
• Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
• Active infection of hepatitis B virus or hepatitis C virus;
• Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving inhaled steroids;
• Previously treated with any CAR-T cell product or other genetically-modified T cell therapies;
• Creatinine>2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin>2.0 mg/dl;
• Other uncontrolled diseases that were not suitable for this trial;
• Patients with HIV infection;
• Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.